免疫检查点抑制剂诱发嗜酸性筋膜炎:药物警戒与EADV专项工作组研究
该回顾性观察研究整合EADV专项工作组、两个国际药物警戒数据库及文献共121例免疫检查点抑制剂诱发嗜酸性筋膜炎(ICI-EF)病例,分析其临床特征、治疗与结局。结果显示最常见基础肿瘤为黑色素瘤(50%),PD-1抑制剂单药治疗占81%,中位起病时间10个月,66%患者症状部分或完全缓解。
要点
- ICI-EF罕见且表现异质,黑色素瘤及PD-1抑制剂单药治疗者最多见。
- 中位起病时间为开始ICI后10个月,临床需警惕延迟出现的肢体肿胀僵硬。
- 多数患者停用ICI并接受全身糖皮质激素治疗,约三分之二获得部分或完全缓解。
核心结论
- ICI-EF是一种罕见的异质性皮肤免疫相关不良事件,可导致显著疾病负担,早期识别和及时治疗是保障ICI继续使用及肿瘤结局的关键。
研究设计与样本
- 回顾性观察研究,纳入EADV专项工作组(n=15)、FPVD(n=21)、VigiBase®(n=45)及文献(n=40)共121例ICI-EF病例,提取人口学、临床特征、诊断、治疗及随访数据。
主要发现
- 所有组中最常见的基础恶性肿瘤为黑色素瘤(50%),最主要的致病药物类别为PD-1抑制剂单药治疗(81%)。
- ICI-EF起病的中位时间为10个月(IQR 6.8-16.3;范围<1-36)。
- 121例中76例(63%)有详细临床信息,临床表现高度异质。
- 治疗以停用ICI(83%)和全身糖皮质激素(80%)为主,其次为甲氨蝶呤(41%)、静脉注射免疫球蛋白(12%)和霉酚酸酯(13%),66%患者ICI-EF症状部分或完全缓解。
临床怎么用
- 对接受ICI治疗尤其是PD-1抑制剂单药治疗的患者,应警惕延迟出现的肢体肿胀、僵硬等嗜酸性筋膜炎表现。
- 确诊ICI-EF后,可考虑停用ICI并给予全身糖皮质激素,必要时联合甲氨蝶呤、静脉注射免疫球蛋白或霉酚酸酯等免疫抑制治疗。
- 早期识别和及时治疗有助于减少长期并发症,并在可能的情况下继续肿瘤治疗以维持肿瘤结局。
局限性
- 本研究为回顾性观察研究,部分病例来自药物警戒数据库和文献,可能存在报告偏倚和信息不完整。
- 121例中仅76例(63%)有详细临床信息,临床表现与治疗结局分析可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the widespread use of immune checkpoint inhibitors (ICI), rare cutaneous immune-related adverse events (cirAEs), including ICI-induced eosinophilic fasciitis (ICI-EF), are increasingly encountered. However, data on its clinical presentation and optimal therapeutic approaches remain sparse. OBJECTIVES: This study aimed to further characterize the clinical features and outcomes of ICI-EF. METHODS: This retrospective observational study analysed clinical features, treatment strategies and outcomes of ICI-EF cases from EADV Task Force-affiliated dermatology departments, complemented by cases from the current available literature and two international pharmacovigilance databases. Patient demographics, clinical characteristics, diagnostics, treatment and follow-up data were extracted from the medical records and databases. RESULTS: We present 121 ICI-EF cases from the EADV Task Force (n = 15), FPVD (n = 21), VigiBase® (n = 45) and the literature (n = 40). The most prevalent underlying malignancy in all groups was melanoma (50%), with PD-1 inhibitor monotherapy (81%) being the predominant offending drug class. The median time to ICI-EF onset was 10 months (IQR 6.8-16.3; range < 1-36). Detailed clinical information was available for 76 of the 121 cases (63%), revealing a highly variable clinical presentation. Treatment primarily involved ICI discontinuation (83%) and systemic corticosteroids (80%), followed by methotrexate (41%), intravenous immunoglobulins (12%) and mycophenolate mofetil (13%), resulting in the partial or complete resolution of ICI-EF symptoms (66%). CONCLUSIONS: ICI-EF is a rare heterogeneous cirAE with varying clinical features and significant morbidity. Early recognition and timely treatment are key to ensuring ICI continuation and preserve oncologic outcomes. UNLABELLED: WHAT IS THE DISEASE?: Immune checkpoint inhibitors (ICIs) are widely used cancer treatments that help the immune system fight tumours. In some patients, these drugs can cause side effects involving the skin and connective tissues. One rare but potentially serious side effect is immune checkpoint inhibitor‐induced eosinophilic fasciitis (ICI‐EF), a condition that causes inflammation and thickening of the tissue beneath the skin, leading to pain, swelling and stiffness of the limbs. LOCATION OF THE STUDY: This study included patients from dermatology departments specializing in supportive oncodermatology and affiliated with the European Academy of Dermatology and Venereology (EADV) Task Force, as well as cases reported worldwide through published medical literature and two international pharmacovigilance databases. AIM OF THE STUDY: The aim was to better describe how ICI‐EF presents in clinical practice and how it is diagnosed and treated. METHODOLOGY: We performed a retrospective observational study including 121 patients with ICI‐EF. Data were collected from hospital records, published case reports and international safety databases. We analysed patient characteristics, symptoms, diagnostic findings, treatments and outcomes. KEY FINDINGS: ICI‐EF most often occurred in patients treated for melanoma and was mainly associated with PD‐1 inhibitor therapy. Symptoms usually developed several months after starting immunotherapy and varied widely between patients. Most patients were treated with stopping the ICI and using systemic corticosteroids, often combined with other immune‐suppressing treatments. About two thirds of patients showed partial or complete improvement. CONCLUSIONS AND PRACTICAL IMPLICATIONS: ICI‐EF is rare but can cause significant symptoms. Early recognition and timely treatment are important to reduce long‐term complications and, where possible, allow continuation of cancer therapy while maintaining good cancer outcomes.
引用
- Bruijn TVM, Gérard AO, Labat M, et al. Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study. J Eur Acad Dermatol Venereol. 2026. PMID: 42253044. doi:10.1111/jdv.70512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。